Join Eupraxia Pharmaceuticals for a virtual KOL event featuring key opinion leader (KOL) Evan Dellon, MD, MPH (University of North Carolina, Chapel Hill), who will join company management to discuss additional clinical data from Eupraxia’s Phase 1b/2a RESOLVE Study evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE).

Dr. Dellon will join Eupraxia’s CEO, Dr. James Helliwell, to discuss the unmet need and current treatment landscape for EoE, and how the collective safety and efficacy data from the RESOLVE study continues to demonstrate the potential for EP-104GI to become a new standard of care for treatment of EoE.

A live question and answer session will follow the formal presentations.